Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.74 |
| ▸ | ITGAV | P06756 | 20/20 | 0.74 |
| ▸ | ITGB1 | P05556 | 16/20 | 0.59 |
| ▸ | ITGA5 | P08648 | 16/20 | 0.59 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.51 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6175851 | 1.00 | ITGB3 (0.74) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL6175847 | 1.00 | ITGB3 (0.74) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL6180607 | 0.88 | ITGB3 (0.74) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL6177505 | 0.86 | ITGB3 (0.75) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL6177136 | 0.85 | ITGB3 (1.00) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL6176301 | 0.85 | ITGB3 (1.00) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL6490652 | 0.85 | ITGB3 (0.73) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL1822558 | 0.84 | ITGB3 (0.69) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL6176398 | 0.84 | ITGB3 (0.79) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL6176294 | 0.83 | ITGB3 (0.73) | ITGB3ITGAVITGB1ITGA5ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020147334-A1 | Vitronectin Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | claimed |
| EP-1061921-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20020147334-A1 | Vitronectin Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| EP-1061921-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999045927-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147334-A1 | Vitronectin Receptor Antagonists | ADGRF1, FN1, CALCR | ITGB3 82/4885ITGAV 146/4885ITGB1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.